Erectile Dysfunction Associated With Type 2 Diabetes Mellitus
Conditions
Keywords
Tadalafil, Endothelin-1, E-selectin, Diabetic complications, Sexual dysfunction, ELISA
Brief summary
This study evaluates the effect of 5 mg daily tadalafil therapy on serum levels of Endothelin-1 and E-selectin in diabetic male patients with erectile dysfunction. Outcomes will be compared pre- and post-treatment versus healthy controls.
Interventions
Oral administration of inert methyl cellulose placebo tablets once daily for 3 months. Used as a comparator in healthy control participants to evaluate changes in Endothelin-1 and E-selectin serum levels.
Sponsors
Study design
Eligibility
Inclusion criteria
Male patients aged between 30 and 60 yearsز Diagnosed with diabetes mellitus Suffering from erectile dysfunction No history of hypertension or other systemic diseases
Exclusion criteria
History of pelvic trauma or major pelvic surgery Pacientes con hipogonadismo o hiperprolactinemia Chronic liver disease or cardiovascular disorders Chronic use of central nervous system drugs, anti-androgenic drugs, or Tramadol Smokers Non-vasculogenic erectile dysfunction Known allergy to tadalafil
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Effect of tadalafil 5 mg on serum levels of Endothelin-1 and E-selectin | 3 months after intervention | Measurement of serum Endothelin-1 and E-selectin concentrations in diabetic patients with erectile dysfunction, before and after daily tadalafil 5 mg for 3 months, using ELISA technique. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Biochemical assessment of serum Endothelin-1 and E-selectin levels | 3 months after intervention | Measurement of serum levels of Endothelin-1 and E-selectin in diabetic patients with erectile dysfunction using ELISA technique before and after tadalafil 5 mg daily treatment. |